. . . . "25"^^ . . . . . . . . . . . . . . . . . . . . . . . "NCT03581292" . . . . . . . . . . . . . . . . "klinisch onderzoek"@nl . . . . . . . . . . . . . . . "A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations"@en . . . . . . . . . . . . "2024-10-29T00:00:00Z"^^ . . . "115"^^ . . . . . . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . . . . . . . . . . . . . . "2018-10-31T00:00:00Z"^^ . . . . . . . . "3"^^ . . . . . . . . . . . . . "Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations"@en . . . . . . "Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations"@en . . "clinical trial"@en . . "Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations"@en . . . . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . . . . . . . . . . .